The Journal of Urology
Volume 177, Issue 1 , Pages 131-138 , January 2007

Recurrence Pattern and Proposed Surveillance Protocol Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection

  • Philippe E. Spiess

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Gordon A. Brown

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Ping Liu

      Affiliations

    • Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Shi-Ming Tu

      Affiliations

    • Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Nizar M. Tannir

      Affiliations

    • Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • James G. Evans

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Ashish M. Kamat

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Financial interest and/or other relationship with Abbott, AstraZeneca and TetraLogic.
    • ,
  • Wassim Kassouf

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Nothing to disclose.
    • ,
  • Louis L. Pisters

      Affiliations

    • Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Corresponding Author InformationCorrespondence: Department of Urology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (telephone: 713-792-3250; FAX: 713-794-4824).
    • Financial interest and/or other relationship with Abbott Pharmaceuticals and Endocare.

Received 3 February 2006

References 

  1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER Cancer Statistics Review, 1975–2002. Based on November 2004 SEER data submission, posted to the SEER website 2005. Bethesda, MD: National Cancer Institute; 2005;
  2. Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer (impact of patient selection factors on outcome). J Clin Oncol. 2005;23:2781
  3. Donohue JP, Thornhill JA, Foster RS, Bihrle R, Rowland RG, Einhorn LH. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer (the Indiana University experience (1965 to 1989)). J Urol. 1995;153:85
  4. Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, et al. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis (follow-up of 50 patients). J Clin Oncol. 1987;5:906
  5. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors (current concepts and controversies). Semin Urol Oncol. 2002;20:262
  6. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD, et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003;21:3310
  7. Donohue JP. Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol Oncol. 2003;21:129
  8. Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, et al. Postchemotherapy residual masses in germ cell tumor patients (content, clinical features, and prognosis). Medical Research Council Testicular Tumour Working Party, Cancer. 1998;83:1409
  9. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163
  10. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174:466
  11. Kaplan EL, Meier EP. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457
  12. Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol. 2004;172:58
  13. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol. 1995;13:1170
  14. Shahidi M, Norman AR, Dearnaley DP, Nicholls J, Horwich A, Huddart RA. Late recurrence in 1263 men with testicular germ cell tumors (Multivariate analysis of risk factors and implications for management). Cancer. 2002;95:520
  15. Dieckmann KP, Albers P, Classen J, DeWit M, Pichlmeier U, Rick O, et al. Late relapse of testicular germ cell neoplasms (a descriptive analysis of 122 cases). J Urol. 2005;173:824
  16. Ronnen EA, Kondagunta GV, Bacik J, Marion S, Bajorin DF, Sheinfeld J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol. 2005;23:6999
  17. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, van Leeuwen FE, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89:1429
  18. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, et al. Second cancer risk following testicular cancer (a follow-up study of 1,909 patients). J Clin Oncol. 1993;11:415
  19. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients (focus on long-term survivors). J Natl Cancer Inst. 2005;97:1354
  20. Gerl A, Schierl R. Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol. 2000;39:519

 Study received Institutional Review Board approval.For another article on a related topic see page 395.Editor’s Note: This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 410 and 411.

PII: S0022-5347(06)02168-9

doi: 10.1016/j.juro.2006.08.092

The Journal of Urology
Volume 177, Issue 1 , Pages 131-138 , January 2007

Article Tools

* Image Usage & Resolution